ArticleBMC cancer2023

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial.

Satoru Miura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.